
|Videos|April 8, 2022
Residual Cardiovascular Risk
Ian Riddock, MD, describes residual cardiovascular risk, both with and without the use of statin therapies.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
'Tis the Season: SABCS 2025 to Highlight Latest Advances Across the Breast Cancer Continuum
2
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
3
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
4
Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML
5
















































